Movement, page-6

Plough,

''we have a product that will probably be low cost to produce compared to any competition''

All nrt have at present is 3 drug candidates which only have pre clinical findings on mice and test tubes with around $40m to pursue their potential success over the next number of years

The market is up 120 points and yet NRT still at 14.5c

DYOR